Overview

Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
Phase:
Phase 2
Details
Lead Sponsor:
Kowa Research Institute, Inc.
Treatments:
Pharmaceutical Solutions